Leber-like hereditary optic neuropathy, autosomal recessive 1

Summary

Leber-like hereditary optic neuropathy, autosomal recessive 1 (MONDO:0958183) is a disease caused by DNAJC30 (GenCC Strong), with 1 cohort gene.

At a glance

• Causal gene: DNAJC30 (GenCC Strong)
• Cohort genes: 1
• ClinVar variants: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Leber-like hereditary optic neuropathy, autosomal recessive 1
Mondo ID	MONDO:0958183
OMIM	619382
GARD	0026960
Is cancer (heuristic)	no

Data availability: 8 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: human disease › disease by developmental or physiological process › metabolic disease › developmental anomaly of metabolic origin › inborn mitochondrial metabolism disorder › mitochondrial oxidative phosphorylation disorder › mitochondrial respiratory chain complex deficiency › mitochondrial complex I deficiency › mitochondrial complex I deficiency, nuclear type › Leber hereditary optic neuropathy, autosomal recessive › Leber-like hereditary optic neuropathy, autosomal recessive 1

Related subtypes (1): Leber-like hereditary optic neuropathy, autosomal recessive 2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

8 retrieved; paginated sample, class counts are floors:

5 pathogenic, 2 uncertain significance, 1 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1171026	NM_032317.3(DNAJC30):c.232C>T (p.Pro78Ser)	DNAJC30	Pathogenic	no assertion criteria provided
1171027	NM_032317.3(DNAJC30):c.302T>A (p.Leu101Gln)	DNAJC30	Pathogenic	no assertion criteria provided
2628014	NM_032317.3(DNAJC30):c.130_131del (p.Ser44fs)	DNAJC30	Pathogenic	no assertion criteria provided
2628015	NM_032317.3(DNAJC30):c.610G>T (p.Glu204Ter)	DNAJC30	Pathogenic	no assertion criteria provided
2628016	NM_032317.3(DNAJC30):c.227ACC[1] (p.His77del)	DNAJC30	Pathogenic	no assertion criteria provided
976691	NM_032317.3(DNAJC30):c.152A>G (p.Tyr51Cys)	DNAJC30	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3251975	NM_032317.3(DNAJC30):c.233C>G (p.Pro78Arg)	DNAJC30	Uncertain significance	criteria provided, single submitter
3901958	NM_032317.3(DNAJC30):c.*122C>T	DNAJC30	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 4 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
DNAJC30	Strong	Autosomal recessive	Leber hereditary optic neuropathy, autosomal recessive	4

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
DNAJC30	Orphanet:104	Leber hereditary optic neuropathy
DNAJC30	Orphanet:904	Williams syndrome

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
DNAJC30	HGNC:16410	ENSG00000176410	Q96LL9	DnaJ homolog subfamily C member 30, mitochondrial	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
DNAJC30	DnaJ homolog subfamily C member 30, mitochondrial	Mitochondrial protein enriched in neurons that acts as a regulator of mitochondrial respiration.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
DNAJC30	Other/Unknown	no		DnaJ_domain, J_dom_sf, Mito_ATP_Synthase-Asso

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
kidney epithelium	1
pancreatic ductal cell	1
tibialis anterior	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
DNAJC30	255	ubiquitous	marker	tibialis anterior, pancreatic ductal cell, kidney epithelium

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
DNAJC30	1,484

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
DNAJC30	Q96LL9	1

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of mitochondrial ATP synthesis coupled proton transport	1	5617.3×	5e-04	DNAJC30
ATP biosynthetic process	1	991.3×	0.002	DNAJC30
brain development	1	79.5×	0.013	DNAJC30

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
DNAJC30	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	DNAJC30

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DNAJC30	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.